Tags

Type your tag names separated by a space and hit enter

Current concepts about chromium supplementation in type 2 diabetes and insulin resistance.
Curr Diab Rep 2010; 10(2):145-51CD

Abstract

Chromium has been established to be an essential trace element in mammals in regard to maintenance of normal carbohydrate metabolism. Studies that provided chromium to human subjects in documented deficiency states noted improved glucose levels. However, controversy exists as to whether dietary supplementation with chromium should be routinely recommended in subjects without documented deficiencies. Over the recent past, several well-designed clinical trials have provided evidence in favor of and against a beneficial effect of chromium. It appears that across all subject phenotypes (eg, lean and obese, insulin sensitive and insulin resistant), a consistent significant and beneficial effect of chromium may not be observed. Specifically, recent data fail to demonstrate significant improvement in carbohydrate metabolism in individuals with metabolic syndrome, impaired glucose tolerance, or consistently in individuals with type 2 diabetes. However, patient selection may be an important factor in determining clinical response, as it was concluded that a clinical response to chromium (ie, decreased glucose and improved insulin sensitivity) may be more likely in insulin-resistant individuals with type 2 diabetes who have more elevated fasting glucose and hemoglobin A(1c) levels.

Authors+Show Affiliations

Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.No affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

20425574

Citation

Wang, Zhong Q., and William T. Cefalu. "Current Concepts About Chromium Supplementation in Type 2 Diabetes and Insulin Resistance." Current Diabetes Reports, vol. 10, no. 2, 2010, pp. 145-51.
Wang ZQ, Cefalu WT. Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. Curr Diab Rep. 2010;10(2):145-51.
Wang, Z. Q., & Cefalu, W. T. (2010). Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. Current Diabetes Reports, 10(2), pp. 145-51. doi:10.1007/s11892-010-0097-3.
Wang ZQ, Cefalu WT. Current Concepts About Chromium Supplementation in Type 2 Diabetes and Insulin Resistance. Curr Diab Rep. 2010;10(2):145-51. PubMed PMID: 20425574.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. AU - Wang,Zhong Q, AU - Cefalu,William T, PY - 2010/4/29/entrez PY - 2010/4/29/pubmed PY - 2010/10/1/medline SP - 145 EP - 51 JF - Current diabetes reports JO - Curr. Diab. Rep. VL - 10 IS - 2 N2 - Chromium has been established to be an essential trace element in mammals in regard to maintenance of normal carbohydrate metabolism. Studies that provided chromium to human subjects in documented deficiency states noted improved glucose levels. However, controversy exists as to whether dietary supplementation with chromium should be routinely recommended in subjects without documented deficiencies. Over the recent past, several well-designed clinical trials have provided evidence in favor of and against a beneficial effect of chromium. It appears that across all subject phenotypes (eg, lean and obese, insulin sensitive and insulin resistant), a consistent significant and beneficial effect of chromium may not be observed. Specifically, recent data fail to demonstrate significant improvement in carbohydrate metabolism in individuals with metabolic syndrome, impaired glucose tolerance, or consistently in individuals with type 2 diabetes. However, patient selection may be an important factor in determining clinical response, as it was concluded that a clinical response to chromium (ie, decreased glucose and improved insulin sensitivity) may be more likely in insulin-resistant individuals with type 2 diabetes who have more elevated fasting glucose and hemoglobin A(1c) levels. SN - 1539-0829 UR - https://www.unboundmedicine.com/medline/citation/20425574/Current_concepts_about_chromium_supplementation_in_type_2_diabetes_and_insulin_resistance_ L2 - https://dx.doi.org/10.1007/s11892-010-0097-3 DB - PRIME DP - Unbound Medicine ER -